In 2023, the Oregon Legislature expanded the board’s mission through Senate Bill 192 to “develop a plan for establishing upper payment limits on drugs sold in this state that are subject to affordability reviews under ORS 646A.694.” An upper payment limit (UPL) limits what purchasers in Oregon will pay for specific drugs.
The Prescription Drug Affordability Board has been working with consultants, Myers and Stauffer LC, on an upper payment limit study. As part of the study, consultants held 23 community meetings and focus groups this past April through July, surveying constituents and compiling feedback. The board also hosted question and answer sessions with constituents during the July 24 board meeting.
The UPL report will include the constituent engagement portion, recommendations for board consideration, and concepts for implementing an upper payment limit in Oregon. The board has been reviewing portions of the report and will continue the discussion at the Oct. 16 meeting. The board will consider the final report for approval at the Nov. 20 board meeting. The board will provide the report to the Oregon Legislature at the end of November.
This page has all the board resources for the UPL study, with links to draft reports, slideshows, documents submitted by constituents, and video recordings.